The current ELN management guidelines suggest the usage of Midostaurin during induction, maintenance, and consolidation for AML patients with FLT3 mutations who are fit for intensive chemotherapy, and for patients unfit for an intensive regimen, gilternib as a single agent is recommended [8]. The gene discussed is FLT3; the disease is acute myeloid leukemia.